Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Apr 12, 2017
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rexahn Pharmaceuticals, Inc.
|
0
|
$0.51 | -$97,875.00 |
—
| 6.01M |
Apr 10
|
Scheduled
| ||||||
Rexahn Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jan 20
| |||||||
Rexahn Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jan 28
| |||||||
Rexahn Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jan 23
| |||||||
Rexahn Pharmaceuticals, Inc.
|
0
|
$0.86 | -$35,047.57 |
—
| 6.01M |
Jan 8 - Jan 12
|
Scheduled
| ||||||
Rexahn Pharmaceuticals, Inc.
| -803.92K |
—
|
—
| -11.80% | 6.01M |
Dec 18
| |||||||
Rexahn Pharmaceuticals, Inc.
|
0
|
$0.90 | -$25,481.71 |
—
| 6.81M |
Jun 12
| |||||||
Rexahn Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jan 12
| |||||||
Rexahn Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
|
Mar 1
| |||||||
Rexahn Pharmaceuticals, Inc.
| 1.01M |
$1.31 | $1,320,582.18 | +9.76% | 11.34M |
May 18
| |||||||
Rexahn Pharmaceuticals, Inc.
| 320.85K |
$1.22 | $391,432.12 | +3.21% | 10.33M |
Apr 1
| |||||||
Rexahn Pharmaceuticals, Inc.
| -510.00K |
—
|
—
| -4.85% | 10.01M |
Dec 14
| |||||||
Rexahn Pharmaceuticals, Inc.
| -2.74M |
$0.68 | $176,800.00 | -20.66% | 10.52M |
Apr 30 - May 4
| |||||||
Rexahn Pharmaceuticals, Inc.
| 10K |
$2.40 | $23,980.00 | +0.07% | 14.01M |
Apr 14
| |||||||
Rexahn Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
|
Dec 8
| |||||||
Rexahn Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||